Researcher
Hugo Vandenplas
- Keywords:Medicine
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From1 Nov 2022 → Today - Clinical sciences (Department)
Member
From1 Jul 2019 → Today - Clinical sciences (Department)
Member
From1 Jul 2019 → 20 Oct 2022 - Clinical sciences (Department)
Member
From7 Dec 2015 → 6 Dec 2017
Publications
1 - 5 of 5
- The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer(2022)
Authors: Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
- Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer(2021)
Authors: Philippe Giron, Carolien Eggermont, Maxim Noeparast, Hugo Vandenplas, Erik Teugels, Ramses Forsyth, Olivier De Wever, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
Pages: 2579-2593 - Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells(2020)
Authors: Sven de Mey, Inès Dufait, H. Jiang, Cyril Corbet, Hui Wang, Melissa Van De Gucht, Lisa Kerkhove, Ka Lun Law, Hugo Vandenplas, Thierry Gevaert, et al.
Pages: 1-20 - CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition(2019)
Authors: Maxim Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève, et al.
Pages: 5933-5941 - Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2(2016)
Authors: Zhuo Ren, Joeri L Aerts, Hugo Vandenplas, Jiance A Wang, Olena Gorbenko, Jack P Chen, Philippe Giron, Carlo Heirman, Cleo Goyvaerts, Eldad Zacksenhaus, et al.